Affy to Buy ParAllele for $120M in Stock; Deal Expected to Close in Q3 | GenomeWeb

NEW YORK, May 31 (GenomeWeb News) - Affymetrix said today that it plans to acquire privately held ParAllele BioScience for approximately $120 million in stock.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.